Clinical trial
Safety of Daily Dose Esomeprazole for GERD for Pediatric and Adolescent Patients
NCT00241501 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00241501 |
|---|---|
| Title | Safety of Daily Dose Esomeprazole for GERD for Pediatric and Adolescent Patients |
| Official title | A Phase III, Multicentre, Randomized, Double-blind, Parallel-group Study to Evaluate the Safety of Once Daily Esomeprazole for the Treatment of Clinically Diagnosed Gastroesophageal Reflux Disease (GERD) in Pediatric and Adolescent Patients 12 to 17 Years of Age, Inclusive. |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Gastroesophageal Reflux Disease (GERD) |
| Intervention type | Drug |
| Interventions | Esomeprazole (Nexium) |
| Enrollment | 140 |
| Start date | Feb 1, 2004 |
| Completion | Apr 1, 2005 |
| First posted | Oct 19, 2005 |
| Last update posted | Nov 19, 2010 |
| Countries | Canada, France, Italy, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: